LENZ Therapeutics (LENZ) News
NASDAQ: LENZHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.97-0.375 (-11.23%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LENZ news summary
We found 3 recent headlines mentioning LENZ Therapeutics (LENZ): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. LENZ is making an outsized move today, down 11.23% at $2.97, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "LENZ (LENZ) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 2, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest LENZ Therapeutics headlines
- LENZ (LENZ) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO SuccessionQ3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increasesGlobeNewswire
- Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseRegeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqREGN, LENZ